Nanobiotix secures collaboration for lead product

Tuesday 7 August 2012

Nanobiotix SA of France has secured a development partnership for its lead product, a nanoparticle device that is intended to enhance the efficacy of radiotherapy, with PharmaEngine Inc of Taiwan. The upfront payment is $1 million.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

France